Huang Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huang Zeng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Bo Qiu
Medical College, Jiaying University, Meizhou 514031, China
2 shared publications- Hao Yang
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
2 shared publications Hua Nie
Medical College, Jiaying University, Meizhou 514031, China
2 shared publicationsJiayao Liu
Medical College, Jiaying University, Meizhou 514031, China
2 shared publicationsJiunlong Yang
Medical College, Jiaying University, Meizhou 514031, China
2 shared publicationsLingfeng Wu
Medical College, Jiaying University, Meizhou 514031, China
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (40) , 47155-47170
Discovery of a potent TDP1 inhibitor through machine learning-driven predictive modeling combined with structure-based virtual screening and experimental validation
An integrated workflow combining machine learning-based predictive modeling with structure-based virtual screening and experimental validation, leading to the discovery of AO65 as a potent TDP1 inhibitor.
- 3 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (40) , 47155-47170
Open AccessDiscovery of a potent TDP1 inhibitor through machine learning-driven predictive modeling combined with structure-based virtual screening and experimental validation
An integrated workflow combining machine learning-based predictive modeling with structure-based virtual screening and experimental validation, leading to the discovery of AO65 as a potent TDP1 inhibitor.
- 21 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10788-10810
Design, Synthesis and Biological Evaluation of 6H-Benzimidazo[1′,2′:1,2]pyrido[3,4- b ]indole Derivatives as TDP1 Inhibitors: Potent Synergistic Agents with Topotecan against Cervical Cancer
Cervical cancer remains a major global threat to women's health. Topotecan (TPT), a topoisomerase I (TOP1) inhibitor, is widely used for advanced or recurrent disease; however, its efficacy is compromised by tyrosyl-DNA phosphodiesterase 1 (TDP1)-mediated DNA repair. Moreover, effective TDP1 inhibitors remain limited. In this study, we modified the lead compound 3b based on the 6H-benzimidazo[1',2':1,2]pyrido[3,4-b]indole scaffold to synthesize derivatives. Derivative 16b exhibited the most potent TDP1 inhibitory activity (IC50 = 1.52 ± 0.34 μM). Molecular docking and dynamics simulations revealed that 16b simultaneously occupied TDP1's catalytic and DNA-binding domains. Furthermore, 16b synergized with TPT to suppress HeLa cell proliferation. This effect was likely mediated by enhanced DNA damage, induced apoptosis, S-phase cell cycle arrest, and potentially ferroptosis. In vivo, the combination treatment significantly inhibited tumor growth in cervical cancer xenograft models. These findings identify 16b as a promising TDP1 inhibitor with potential to enhance TPT-based therapy.
- 21 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10788-10810
Design, Synthesis and Biological Evaluation of 6H-Benzimidazo[1′,2′:1,2]pyrido[3,4- b ]indole Derivatives as TDP1 Inhibitors: Potent Synergistic Agents with Topotecan against Cervical Cancer
Cervical cancer remains a major global threat to women's health. Topotecan (TPT), a topoisomerase I (TOP1) inhibitor, is widely used for advanced or recurrent disease; however, its efficacy is compromised by tyrosyl-DNA phosphodiesterase 1 (TDP1)-mediated DNA repair. Moreover, effective TDP1 inhibitors remain limited. In this study, we modified the lead compound 3b based on the 6H-benzimidazo[1',2':1,2]pyrido[3,4-b]indole scaffold to synthesize derivatives. Derivative 16b exhibited the most potent TDP1 inhibitory activity (IC50 = 1.52 ± 0.34 μM). Molecular docking and dynamics simulations revealed that 16b simultaneously occupied TDP1's catalytic and DNA-binding domains. Furthermore, 16b synergized with TPT to suppress HeLa cell proliferation. This effect was likely mediated by enhanced DNA damage, induced apoptosis, S-phase cell cycle arrest, and potentially ferroptosis. In vivo, the combination treatment significantly inhibited tumor growth in cervical cancer xenograft models. These findings identify 16b as a promising TDP1 inhibitor with potential to enhance TPT-based therapy.